BioSpace News Archive

Bicara Therapeutics , a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumor microenvironment, today announced that a digital presentation with clinical data from its ongoing Phase 1/2 study of BCA101, a bifunctional antibody designed to target the TGFβ trap to EGFR+ tumors, will be presented at the American Society of Clinical Oncology

Posters to highlight ZYNLONTA ™ LOTIS-2 subgroup analyses, ZYNLONTA ™ LOTIS-5 confirmatory trial and Cami in advanced solid tumors

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on PEPAXTO ® (melphalan flufenamide, also known as melflufen) in relapsed refractory multiple myeloma,

- AnHeart Therapeutics Co., Ltd . (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, announces an upcoming presentation of an abstract selected for poster presentation from its ongoing Phase II trial of taletrectinib in ROS1 fusion positive Non-Small Cell Lung Cancer (NSCLC) (NCT04395677) at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on the first-in-human study of the Bcl-2 inhibitor, lisaftoclax (APG-2575),

ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced the completion of a $26 million Series B financing, led by SPARX Group with participation from Sysmex Corporation and Sumitomo Mitsui Trust Investment as well as existing investors, SBI Group and Itochu Technology Ventures.

Artiva Biotherapeutics appoints Elizabeth L. Hougen, EVP and CFO of Ionis Pharmaceuticals, Inc., has extensive experience in finance and business for public life sciences companies Linda M. Kozick, who led the immuno-oncology product and portfolio strategy for BMS, including Opdivo ® and Yervoy ® , has deep expertise in strategic commercial drug development

Latest Funding Fuels World’s Most Advanced BCI Company to Continue Expanding its Platform for Life Changing Applications and Driving Clinical Studies

Data Support Continued Development of Single-course Gene Editing Therapies for Treatment of Cardiovascular Disease, Led by VERVE-101